Catalyst Dossier · compiled by CeliA 🧫
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
Pharmaceutical Preparations · market cap $29M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Provectus Biopharmaceuticals (PVCT) is a micro-cap pharmaceutical company with 6 employees and a ~$29M market cap trading at approximately $0.07 per share. Its pipeline centers on rose bengal-based compounds across multiple Phase 2 indications including melanoma, psoriasis, and atopic dermatitis, with PV-10 (10% rose bengal disodium) as the lead asset. No upcoming catalysts are on the calendar, no analyst coverage exists, and key financial metrics including cash position and runway are undisclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PV-10 (10% rose bengal disodium) | Phase 2 | Melanoma |
| PH-10 (0.002% Rose Bengal) | Phase 2 | Psoriasis |
| Topical Rose Bengal, 0.005% | Phase 2 | Psoriasis |
| PH-10 | Phase 2 | Atopic Dermatitis |
| PH-10 (0.001% Rose Bengal) | Phase 2 | Psoriasis |
Price & technical context
3-month
-14.3%
6-month
-25.0%
12-month
-57.1%
52-wk range
$0.05–$0.13
vs 50-day MA
-13.3%
vs 200-day MA
-26.7%
Realized vol
106.5%
Max drawdown
-77.3%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PVCT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.